Immuron Ltd
No SEC Form 4 filings for $IMRN in the last 30 days.
See all $IMRN insider activity →Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported FY26 results exceeding expectations, with sales up 6% to A$7.7M and net profit up AUD$1.4M. Key milestones include FDA approval for IMM-529 and growth in Travelan® sales. The company plans to focus on North American expansion and partnering in FY27.
Immuron Limited (ASX: IMC, NASDAQ: IMRN) reported unaudited FY26 Travelan sales growth. Global FY26 sales were AUD 7.7 million, up 6% year over year, with 2H at AUD 3.5 million (+7%) and 4Q at AUD 2.0 million (+2%). Australia FY26 was AUD 5.8 million (+10%), while Canada fell to AUD 0.2 million (-55%) and the U.S. rose to AUD 1.8 million (+7%).
Immuron Limited (ASX: IMC; NASDAQ: IMRN) said it hired Pullan Consulting to help secure a strategic partner for IMM-529, its Phase 2 program to prevent or treat Clostridioides difficile infection. Immuron has FDA IND approval (IND 32095) and is running a randomized, double-blind placebo-controlled trial (up to 60 subjects). Lumanity estimates base-case yearly revenue of about $400M if successful.
Over the past 7 days, alphai's AI scored 1 news story mentioning IMRN (Immuron Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IMRN coverage spans financial news, earnings and market movers.
Preliminary FY26 results beat internal expectations, showing modest revenue growth and profit expansion.
Follow-on sales update suggests improving demand and marketing effectiveness for Travelan, with FX as a partial offset.
Partnering push around an FDA-cleared Phase 2 asset can improve deal odds and near-term sentiment, but no partner terms or trial readout are disclosed.
Immuron's progression of IMM-529 to Phase 2 and strong sales suggest potential upside for the company's stock.
Immuron (ASX:IMC) reports continued sales growth driven by its Travelan immune supplement, with a 5% increase in overall sales to $4.2 million. The positive sales trend suggests potential upward momentum in the stock, especially if growth persists.
alphai scores every news story that mentions IMRN with an AI model for sentiment and relevance, and aggregates insider trades from Immuron Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported FY26 results exceeding expectations, with sales up 6% to A$7.7M and net profit up AUD$1.4M. Key milestones include FDA approval for IMM-529 and growth in Travelan® sales. The company plans to focus on North American expansion and partnering in FY27.
2 min readImmuron Limited (ASX: IMC, NASDAQ: IMRN) reported unaudited FY26 Travelan sales growth. Global FY26 sales were AUD 7.7 million, up 6% year over year, with 2H at AUD 3.5 million (+7%) and 4Q at AUD 2.0 million (+2%). Australia FY26 was AUD 5.8 million (+10%), while Canada fell to AUD 0.2 million (-55%) and the U.S. rose to AUD 1.8 million (+7%).
4 min readImmuron Limited (ASX: IMC; NASDAQ: IMRN) said it hired Pullan Consulting to help secure a strategic partner for IMM-529, its Phase 2 program to prevent or treat Clostridioides difficile infection. Immuron has FDA IND approval (IND 32095) and is running a randomized, double-blind placebo-controlled trial (up to 60 subjects). Lumanity estimates base-case yearly revenue of about $400M if successful.
3 min readImmuron (ASX:IMC) is strengthening its growth profile as its drug candidate IMM-529 progresses to Phase 2 clinical trials for recurrent Clostridioides difficile infection (CDI) after receiving FDA approval. The company is actively seeking a partner to advance IMM-529, which uses a differentiated three-target mechanism, while also reporting strong sales growth across its commercial gastrointestinal health products. This dual focus on pipeline development and commercial performance positions IMM-529 as a key value driver, targeting a significant market opportunity in CDI with sales up 16% in the recent quarter.
4 min readImmuron (ASX:IMC) reported continued sales growth in its key global markets for the first half, driven primarily by strong performance of its Travelan immune supplement in Australia and the United States. The company recorded overall sales of $4.2 million, a 5% increase, with significant gains from marketing efforts and new product launches, despite mixed results in Canada. Immuron aims to expand distribution and leverage its oral immunotherapy platform for future growth.
2 min readImmuron Ltd ADR (NASDAQ:IMRN) stock plunged 24.5% after a clinical trial for an ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint. The company noted that the investigational product was not manufactured by Immuron and was administered differently than its commercial product, Travelan®, citing issues like participant non-compliance and improper administration. Despite the setback, Immuron plans to continue with FDA meetings and existing collaborations, while also advancing discussions for testing Travelan® against other E.coli strains.
4 min readMELBOURNE, Australia, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Immuron Limited ( ASX: IMC. NASDAQ: IMRN ) , an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529.
2 min read
